Lv6
1780 积分 2024-01-09 加入
JHEP Rep. 2025 Oct 11;8(1):101630
2个月前
已完结
Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study
2个月前
已完结
Efficacy and safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies
2个月前
已关闭
Zhu M, et al. Hepatology. 2024 Oct 1;80(4):807-815
2个月前
已完结
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial
2个月前
已完结
Perioperative immunotherapy for resectable hepatocellular carcinoma – Authors’ reply
2个月前
已完结
Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study
2个月前
已完结
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
2个月前
已完结
Causes of Death in Patients with Unresectable Hepatocellular Carcinoma
2个月前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
3个月前
已完结
皖公网安备34019202002308
